Examination of the effect of improving anemia / taste disorder by administration of zinc supplementation to chronic kidney disease exhibiting hypozincemia

Examination of the effect of improving anemia / taste disorder by administration of zinc supplementation to chronic kidney disease exhibiting hypozincemia - Effect of zinc supplementation in patients with chronic kidney disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031655

Enrollment

500

Registered

2018-03-12

Start date

2017-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease Hypozincemia

Interventions

6 months Zn Tablet 50mg/day Everyday, Drug will be increased or decreased depending on blood zinc concentration 6 months No medical intervention

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with chronic kidney disease visiting our hospital (CKD Stage1-2, n =100; Stag3, n =100; Stage4, n =100; Stage5, n =100; Stage 5D, n =100)

Exclusion criteria

Exclusion criteria: 1. We can not obtain consent from patients and their families 2. When the patient's own cognitive decline is strong and it is judged that it is impossible to properly continue the examination 3. Patients who are judged inappropriate as the subject by the research director

Design outcomes

Primary

Measure	Time frame
anemia Changes in subjective symptoms of taste disorder	—

Countries

Japan

Contacts

Public ContactDaisuke Sato

Juntendo University Division of Nephrology

d-sato@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026